Publications by authors named "David Seiden"

Claim this Profile
A
A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome.
Amee Revana, Rakesh Bhattacharjee, Jennifer L Miller, Aaron Chidekel, Priya Khanna, David Seiden

J Clin Sleep Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers.
Richard Bogan, Michael J Thorpy, John W Winkelman, Jordan Dubow, Jennifer Gudeman, David Seiden

Sleep Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
Clete A Kushida, Colin M Shapiro, Thomas Roth, Michael J Thorpy, Bruce C Corser, David Seiden

Sleep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al.
Clete A Kushida, Thomas Roth, Colin M Shapiro, Asim Roy, Russell Rosenberg, David Seiden

Sleep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.
Thomas Roth, Yves Dauvilliers, Michael J Thorpy, Clete Kushida, Bruce C Corser, David Seiden

CNS Drugs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy.
Jordan Dubow, Alon Y Avidan, Bruce Corser, Amod Athavale, David Seiden

Patient Prefer Adherence· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults.
David Seiden, Charles Tyler, Jordan Dubow

Clin Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Crossover, Pharmacokinetics Evaluation of a Novel Continuous Release and Absorption Melatonin Formulation.
David J Seiden, Syed M Shah

Prim Care Companion CNS Disord· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
Peter De Boer, Wayne C Drevets, Hany Rofael, Peter van der Ark, Justine M Kent, David J Seiden

J Psychopharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.
Anuradha Madan, Murdo Ferguson, Paul Rheault, David Seiden, Azhar Toma

Vaccine· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.
Elizabeth Begier, David Joshua Seiden, Michael Patton, Edward Zito, Joseph Severs

Vaccine· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
C Buddy Creech, Robert W Frenck, Eric A Sheldon, David J Seiden, Martin K Kankam

Vaccine· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
Robert W Frenck, C Buddy Creech, Eric A Sheldon, David J Seiden, Martin K Kankam

Vaccine· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.
Russell P Rosenberg, Steven G Hull, D Alan Lankford, David W Mayleben, David J Seiden

J Clin Sleep Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of armodafinil on patient-reported functioning and quality of life in patients with excessive sleepiness associated with shift work disorder: a randomized, double-blind, placebo-controlled trial.
Milton K Erman, Ronghua Yang, David J Seiden

Prim Care Companion CNS Disord· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of armodafinil: effect on clinical condition late in the shift and overall functioning of patients with excessive sleepiness associated with shift work disorder.
Milton K Erman, David J Seiden, Ronghua Yang, Ryan Dammerman

J Occup Environ Med· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia.
Russell Rosenberg, David J Seiden, Steven G Hull, Milton Erman, Howard Schwartz

Sleep· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.
Thomas Roth, Roberta Rogowski, Steven Hull, Howard Schwartz, Gail Koshorek, David Seiden

Sleep· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.
Thomas Roth, David Seiden, Sherry Wang-Weigand, Jeffrey Zhang

Curr Med Res Opin· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial.
R Bruce Lydiard, D Alan Lankford, David J Seiden, Rick Landin, Robert Farber

J Clin Sleep Med· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
Thomas Roth, David Seiden, Stephen Sainati, Sherry Wang-Weigand, Jeffrey Zhang

Sleep Med· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.
Milton Erman, David Seiden, Gary Zammit, Stephen Sainati, Jeffrey Zhang

Sleep Med· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.
Martin Scharf, Milton Erman, Russell Rosenberg, David Seiden, W Vaughn McCall

Sleep· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender discrimination and sexual harassment in medical education: perspectives gained by a 14-school study.
Lois Margaret Nora, Margaret A McLaughlin, Sue E Fosson, Terry D Stratton, Amy Murphy-Spencer, David Seiden

Acad Med· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis